Royal Bank of Canada
JANX icon

Royal Bank of Canada’s Janux Therapeutics JANX Stock Holding History

Royal Bank of Canada’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
28
-1,198
-98% -$16.4K ﹤0.01% 7402
2025
Q4 		$17K Sell
1,226
-330,351
-100% -$7.77M ﹤0.01% 6143
2025
Q3 		$8.1M Sell
331,577
-2,175
-0.7% -$53K ﹤0.01% 2293
2025
Q2 		$7.71M Buy
333,752
+331,996
+18,906% +$8.75M ﹤0.01% 2229
2025
Q1 		$47K Sell
1,756
-14,632
-89% -$552K ﹤0.01% 5594
2024
Q4 		$878K Buy
16,388
+7,369
+82% +$390K ﹤0.01% 3659
2024
Q3 		$410K Sell
9,019
-15,500
-63% -$674K ﹤0.01% 4251
2024
Q2 		$1.03M Buy
24,519
+22,932
+1,445% +$1.08M ﹤0.01% 3436
2024
Q1 		$60K Sell
1,587
-3,110
-66% -$67.7K ﹤0.01% 5457
2023
Q4 		$51K Buy
4,697
+1,300
+38% +$11.2K ﹤0.01% 5984
2023
Q3 		$34K Buy
3,397
+1,614
+91% +$18.6K ﹤0.01% 5978
2023
Q2 		$21K Buy
1,783
+823
+86% +$11K ﹤0.01% 6190
2023
Q1 		$12K Sell
960
-1,221
-56% -$20.3K ﹤0.01% 6233
2022
Q4 		$28K Buy
2,181
+1,947
+832% +$28.5K ﹤0.01% 6161
2022
Q3 		$3K Buy
234
+137
+141% +$1.83K ﹤0.01% 6898
2022
Q2 		$1K Sell
97
-995
-91% -$11.8K ﹤0.01% 7140
2022
Q1 		$16K Sell
1,092
-1,860
-63% -$30.4K ﹤0.01% 6720
2021
Q4 		$58K Buy
2,952
+115
+4% +$2.41K ﹤0.01% 6291
2021
Q3 		$61K Buy
2,837
+1,537
+118% +$44.2K ﹤0.01% 6040
2021
Q2 		$32K Buy
+1,300
New +$29K ﹤0.01% 6304

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Royal Bank of Canada's JANX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Janux Therapeutics (JANX) stake by 98% in Q1 2026, selling an estimated $16.4K and leaving 28 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7402.

Royal Bank of Canada first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $8.1M in Q3 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Royal Bank of Canada held 28 shares of Janux Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 1,198 Janux Therapeutics shares in Q1 2026, an estimated $16.4K.
  • Janux Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7402 holding.
  • Royal Bank of Canada first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Royal Bank of Canada's Janux Therapeutics position peaked at $8.1M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.